Vatiquinone found to slow Friedreich's Ataxia progression by 75% after 1.5 years

But oral therapy fails to meet primary goal in Phase 2/3 trial

#Neuroscience #Brain #NeurologicalDiseases #NeurodegenerativeDiseases #Neurodegeneration #Cerebellum #Ataxia #FriedreichAtaxia #HereditaryAtaxias #Ataxias #NeurogeneticDiseases #Neurogenetics
#Genetics #HereditaryDiseases #GeneticDiseases
#ClinicalTrial
#Vatiquinone #Neuroinflammation
#Biomedicine #Health

https://friedreichsataxianews.com/news/vatiquinone-slows-fa-progression-after-18-months-trial-data/